FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011005066> ?p ?o ?g. }

• W3011005066 abstract "Importance The recommendations about antithrombotic medication use after bioprosthetic aortic valve replacement (bAVR) vary. Objectives To describe the post-bAVR antithrombotic medication practice across the Veterans Health Administration (VHA) and to assess the association between antithrombotic strategies and post-bAVR outcomes. Design, Setting, and Participants Retrospective cohort study. Multivariable modeling with propensity scores was conducted to adjust for differences in patient characteristics across the 3 most common antithrombotic medication strategies (aspirin plus warfarin sodium, aspirin only, and dual antiplatelets). Text mining of notes was used to identify the patients with bAVR (fiscal years 2005-2015). Main Outcomes and Measures This study used VHA and non-VHA outpatient pharmacy data and text notes to classify the following antithrombotic medications prescribed within 1 week after discharge from the bAVR hospitalization: aspirin plus warfarin, aspirin only, dual antiplatelets, no antithrombotics, other only, and warfarin only. The 90-day outcomes included all-cause mortality, thromboembolism risk, and bleeding events. Outcomes were identified using primary diagnosis codes from emergency department visits or hospital admissions. Results The cohort included 9060 veterans with bAVR at 47 facilities (mean [SD] age, 69.3 [8.8] years; 98.6% male). The number of bAVR procedures per year increased from 610 in fiscal year 2005 to 1072 in fiscal year 2015. The most commonly prescribed antithrombotic strategy was aspirin only (4240 [46.8%]), followed by aspirin plus warfarin (1638 [18.1%]), no antithrombotics (1451 [16.0%]), dual antiplatelets (1010 [11.1%]), warfarin only (439 [4.8%]), and other only (282 [3.1%]). Facility variation in antithrombotic prescription patterns was observed. During the 90-day post-bAVR period, adverse events were uncommon, including all-cause mortality in 127 (1.4%), thromboembolism risk in 142 (1.6%), and bleeding events in 149 (1.6%). No differences in 90-day mortality or thromboembolism were identified across the 3 antithrombotic medication groups in either the unadjusted or adjusted models. Patients receiving the combination of aspirin plus warfarin had higher odds of bleeding than patients receiving aspirin only in the unadjusted analysis (odds ratio, 2.58; 95% CI, 1.71-3.89) and after full risk adjustment (adjusted odds ratio, 1.92; 95% CI, 1.17-3.14). Conclusions and Relevance These data demonstrate that bAVR procedures are increasingly being performed in VHA facilities and that aspirin only was the most commonly used antithrombotic medication strategy after bAVR. The risk-adjusted results suggest that the combination of aspirin plus warfarin does not improve either all-cause mortality or thromboembolism risk but increases the risk of bleeding events compared with aspirin only." @default.
• W3011005066 created "2020-03-23" @default.
• W3011005066 creator A5002279941 @default.
• W3011005066 creator A5009792082 @default.
• W3011005066 creator A5039441287 @default.
• W3011005066 creator A5042909938 @default.
• W3011005066 creator A5042973046 @default.
• W3011005066 creator A5044300823 @default.
• W3011005066 creator A5059026251 @default.
• W3011005066 creator A5073429845 @default.
• W3011005066 creator A5078944322 @default.
• W3011005066 creator A5082080121 @default.
• W3011005066 creator A5090525925 @default.
• W3011005066 date "2018-12-26" @default.
• W3011005066 modified "2023-09-24" @default.
• W3011005066 title "Association Between Antithrombotic Medication Use After Bioprosthetic Aortic Valve Replacement and Outcomes in the Veterans Health Administration System" @default.
• W3011005066 hasPublicationYear "2018" @default.
• W3011005066 type Work @default.
• W3011005066 sameAs 3011005066 @default.
• W3011005066 citedByCount "0" @default.
• W3011005066 crossrefType "journal-article" @default.
• W3011005066 hasAuthorship W3011005066A5002279941 @default.
• W3011005066 hasAuthorship W3011005066A5009792082 @default.
• W3011005066 hasAuthorship W3011005066A5039441287 @default.
• W3011005066 hasAuthorship W3011005066A5042909938 @default.
• W3011005066 hasAuthorship W3011005066A5042973046 @default.
• W3011005066 hasAuthorship W3011005066A5044300823 @default.
• W3011005066 hasAuthorship W3011005066A5059026251 @default.
• W3011005066 hasAuthorship W3011005066A5073429845 @default.
• W3011005066 hasAuthorship W3011005066A5078944322 @default.
• W3011005066 hasAuthorship W3011005066A5082080121 @default.
• W3011005066 hasAuthorship W3011005066A5090525925 @default.
• W3011005066 hasConcept C104863432 @default.
• W3011005066 hasConcept C126322002 @default.
• W3011005066 hasConcept C167135981 @default.
• W3011005066 hasConcept C17923572 @default.
• W3011005066 hasConcept C194828623 @default.
• W3011005066 hasConcept C201903717 @default.
• W3011005066 hasConcept C2776301958 @default.
• W3011005066 hasConcept C2777015399 @default.
• W3011005066 hasConcept C2777628954 @default.
• W3011005066 hasConcept C2779161974 @default.
• W3011005066 hasConcept C2909817843 @default.
• W3011005066 hasConcept C512399662 @default.
• W3011005066 hasConcept C71924100 @default.
• W3011005066 hasConcept C72563966 @default.
• W3011005066 hasConceptScore W3011005066C104863432 @default.
• W3011005066 hasConceptScore W3011005066C126322002 @default.
• W3011005066 hasConceptScore W3011005066C167135981 @default.
• W3011005066 hasConceptScore W3011005066C17923572 @default.
• W3011005066 hasConceptScore W3011005066C194828623 @default.
• W3011005066 hasConceptScore W3011005066C201903717 @default.
• W3011005066 hasConceptScore W3011005066C2776301958 @default.
• W3011005066 hasConceptScore W3011005066C2777015399 @default.
• W3011005066 hasConceptScore W3011005066C2777628954 @default.
• W3011005066 hasConceptScore W3011005066C2779161974 @default.
• W3011005066 hasConceptScore W3011005066C2909817843 @default.
• W3011005066 hasConceptScore W3011005066C512399662 @default.
• W3011005066 hasConceptScore W3011005066C71924100 @default.
• W3011005066 hasConceptScore W3011005066C72563966 @default.
• W3011005066 hasOpenAccess W3011005066 @default.
• W3011005066 hasRelatedWork W1757672718 @default.
• W3011005066 hasRelatedWork W1966943635 @default.
• W3011005066 hasRelatedWork W1974852991 @default.
• W3011005066 hasRelatedWork W1985731160 @default.
• W3011005066 hasRelatedWork W1996863467 @default.
• W3011005066 hasRelatedWork W2000789055 @default.
• W3011005066 hasRelatedWork W2026512965 @default.
• W3011005066 hasRelatedWork W2035728361 @default.
• W3011005066 hasRelatedWork W2056859002 @default.
• W3011005066 hasRelatedWork W2163274594 @default.
• W3011005066 hasRelatedWork W2258026212 @default.
• W3011005066 hasRelatedWork W2438145529 @default.
• W3011005066 hasRelatedWork W2556285236 @default.
• W3011005066 hasRelatedWork W2584413368 @default.
• W3011005066 hasRelatedWork W2589128497 @default.
• W3011005066 hasRelatedWork W2604427073 @default.
• W3011005066 hasRelatedWork W2666992979 @default.
• W3011005066 hasRelatedWork W2699048715 @default.
• W3011005066 hasRelatedWork W2996626784 @default.
• W3011005066 hasRelatedWork W2022532301 @default.
• W3011005066 isParatext "false" @default.
• W3011005066 isRetracted "false" @default.
• W3011005066 magId "3011005066" @default.
• W3011005066 workType "article" @default.